Skip to content

A randomized controlled clinical trial of the safety and efficacy of hyperbaric oxygen for delaying aging in healthy older adults

A randomized controlled clinical trial of the safety and efficacy of hyperbaric oxygen for delaying aging in healthy older adults

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400087458
Enrollment
Unknown
Registered
2024-07-29
Start date
2024-10-17
Completion date
Unknown
Last updated
2026-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aging

Interventions

The experiment group :The subjects are made to take in oxygen by masks under 2.0 ATA in chamber. Treatments are given once a day for a total duration of 100 minutes each, 6 times a week.
The control group:The subjects are made to take in oxygen by masks under 1.04 ATA in chamber. Treatments are given once a day for a total duration of 100 minutes each, 6 times a week.

Sponsors

Depart of Plastic & Reconstructive Surgery, The Ninth People's Hospital of Shanghai Jiaotong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >= 60 years (No gender restrictions); 2. No serious organic or psychiatric disease; 3. Not having received hyperbaric oxygen therapy within half a year prior to baseline; 4. Willingness to maintain a consistent diet and lifestyle throughout the study period; 5. Informed consent to the purpose and content of the study.

Exclusion criteria

Exclusion criteria: 1. Patients with comorbid psychiatric disorders; 2. Patients unwilling to sign an informed consent form; 3. Unwillingness to co-operate and factors affecting compliance; 4. Uncontrolled hypertension (systolic blood pressure >= 140 mmHg, and/or diastolic blood pressure >= 90 mmHg); 5. History of hyperbaric oxygen therapy within six months prior to baseline; 6. Severe pulmonary dysfunction; 7. History of malignancy in the past year; 8. Pathological cognitive decline; 9. Severe chronic renal failure (GFR = 8%, and/or fasting blood glucose >= 11.1 mmol/L); 11. Receiving immunosuppressive therapy.

Design outcomes

Primary

MeasureTime frame
Senescence-associated secretory phenotype;

Secondary

MeasureTime frame
Blood routine examination;Blood biochemical examination;Oxidative stress levels in serum samples;Dermoscopic features ;Life quality score;Multi-omics sequencing and joint analysis;Carotid artery ultrasound;Body composition examination;Behavioral tests;Pulmonary function test;

Countries

China

Contacts

Public ContactCaiyue Liu

Depart of Plastic & Reconstructive Surgery, The Ninth People's Hospital of Shanghai Jiaotong University School of Medicine

yueyue1888@hotmail.com+86 158 0034 5685

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 16, 2026